The people's voice of reason
The people's voice of reason
Weight loss has become easier to achieve, but the tradeoffs aren’t always apparent right away. For many patients starting GLP-1 medications, the early results can feel drastic, even disorienting, NutraBio reports.
Taryn J. Mitchell, a 54-year-old banker from Greensboro, North Carolina, began losing weight rapidly after starting Wegovy, without the strict diet and exercise routine she had relied on for years. But alongside that progress came something less expected. “It got scary,” she said, as the pace of weight loss raised new concerns about strength and muscle.
Clinicians say the concern is not unfounded, even if the science is still evolving. Weight loss has always included some reduction in lean mass. However, what is changing is the speed and scale. The drugs change appetite. But now patients must change their nutrition as well.
The scale of adoption helps explain why this tension is gaining national attention now. A November 2025 KFF Health Tracking Poll found roughly one in eight American adults currently taking a GLP-1 medication, with nearly one in five having used one at some point. Use is highest among adults aged 50 to 64, a group already navigating changes in muscle and metabolism.
As use expands, attention is turning to body composition rather than weight alone. Early evidence suggests a meaningful share of weight lost can include lean mass, with outcomes shaped by diet, activity, age, and the pace of loss. That reality is beginning to influence behavior beyond the clinic.
Justin Bina, an assistant professor at Arizona State University, notes that GLP-1 adoption is already reshaping demand. "We find that GLP-1 adoption directly increases what users are willing to pay for protein products," he said, adding that manufacturers and restaurants are responding with "GLP-1-friendly" products positioned around nutrient density and protein.
In the STEP-1 trial — the foundational study behind Wegovy's approval — a subgroup of participants underwent dual-energy X-ray absorptiometry, an imaging technique that separates fat from lean tissue with more precision than a standard scale.
Among those participants, semaglutide produced an average 15% reduction in body weight over 68 weeks, with fat mass dropping roughly 19% and lean body mass declining about 10%. Notably, the proportion of lean mass relative to total body weight actually increased, because fat dropped more.
A similar pattern emerged in the SURMOUNT-1 trial examining tirzepatide: Participants lost an average 21% of body weight over 72 weeks, with approximately 75% of that loss attributable to fat and 25% to lean mass — a ratio consistent across age, sex, and weight-loss magnitude subgroups.
Both findings carry an important qualifier. The DXA analyses were conducted on small subsets of each trial population — 140 participants in STEP-1, 160 in SURMOUNT-1 — making them indicative rather than definitive. And the pattern itself is not unique to GLP-1-based weight loss.
"No matter how much weight you lose, about 25% of that will be from muscle," says Dr. Caroline Apovian, co-director for Weight Management and Wellness at Harvard-affiliated Brigham and Women's Hospital. "And if you lose a lot of weight quickly, as can happen when you use GLP-1s or follow an extreme low-carb or low-calorie diet, you can lose even more muscle and at a faster rate."
The stakes of that loss matter beyond appearance. "Skeletal muscle is not just tissue that helps us move," says Dr. Sangeeta Kashyap of New York-Presbyterian/Weill Cornell Medical Center. "It's our most metabolically active organ. It burns 80% of glucose post-meal and 20-30% of fat at rest, regulates insulin sensitivity, supports immune health, and helps maintain our resting metabolic rate."
Research on mitigation points consistently in two directions: higher protein intake and resistance training.
Reviews and meta-analyses generally support protein intakes in the range of 1.2 to 1.6 grams per kilogram of body weight per day during energy restriction, substantially higher than standard dietary recommendations.
In controlled hypocaloric trials, higher protein intake preserved lean mass more effectively than lower protein intake. Meta-analytic evidence, particularly in older adults, further supports pairing resistance exercise with adequate protein to improve muscle mass and strength outcomes, though results vary by population and protocol.
Much of the data comes from substudies, short-term trials, or specific populations, and results vary depending on protocol and adherence. The broader takeaway is less about eliminating lean-mass loss and more about managing it, with approaches that need to be adapted to individual health status, including age, comorbidities, and overall treatment goals.
Appetite suppression is the mechanism that makes GLP-1s effective, and it is the same mechanism that makes adequate protein intake difficult to sustain. Patients eating significantly smaller portions are often not prioritizing protein — they are eating whatever feels tolerable, which tends to mean bland, carbohydrate-heavy foods that are easier on a sensitive stomach.
GI side effects, including nausea and early fullness, compound the pattern. The result is that many users are losing weight while quietly undereating the one macronutrient most critical to preserving what they are trying to keep.
Clinical guidance published in 2025 reinforces that point, noting that adequate protein may be difficult to achieve for GLP-1 users due to reduced appetite and taste aversions, and recommending a protein-first approach at meals alongside structured resistance training at least three times per week.
Yet many patients are focused on the number on the scale, not on strength, and are skipping the resistance work entirely.
"The goal is fat loss, not muscle loss," says Dr. Soohan Mansuri, a board-certified primary care physician with the Torrance Memorial Physician Network. "Without intentional protein intake and resistance exercise, muscle mass declines — and so does metabolism."
The stakes are not equal across populations. Older adults and postmenopausal women often enter treatment with lower baseline muscle mass, meaning the same proportional loss carries heavier functional consequences.
"When calories are restricted, adequate protein becomes essential to maintain muscle," says Dr. Kashyap, who recommends working with a nutritionist to make every meal count as appetite patterns change during treatment.
As GLP-1 adoption has scaled across nearly 12% of U.S. adults, food manufacturers, supplement brands, and restaurant chains have moved aggressively to meet the appetite-suppressed, protein-conscious consumer — with products explicitly built around the medication's side effects and nutritional demands.
The response on store shelves has been concrete. Nestlé launched Vital Pursuit, a frozen meal line designed around the nutritional profile of GLP-1 users, and later added "GLP-1 Friendly" labeling after customers requested it.
Conagra followed, adding its "On Track" badge to 26 Healthy Choice products in early 2025.
Smoothie King built a GLP-1 Support Menu in partnership with a registered dietitian.
Danone reported that yogurt consumption is nearly three times higher in households using GLP-1 medications. It responded with new protein shakes carrying 30 grams of protein per serving, a cultured dairy drink formulated to support muscle retention, and a plant-based milk with added protein.
Restaurant chains, including Chipotle and Shake Shack, cited GLP-1 users when debuting protein-forward menu items.
Protein from whole foods combined with resistance training remains the evidence-based foundation for lean mass preservation. The question the market has not answered is whether reformulated packaging addresses a genuine nutrition gap. Or monetizes the anxiety around one.
“GLP-1 medications are powerful tools, but they don’t replace the fundamentals of nutrition and physical activity,” says Matt Weik, BS, CSCS, CPT, CSN from NutraBio.
For anyone currently on a GLP-1 medication, the clinical guidance points in a consistent direction. Prioritize protein at the start of meals, when appetite is highest, and spread intake across the day rather than concentrating it in one sitting.
Reviews and meta-analyses on weight loss and lean mass preservation generally reference intakes in the range of 1.2 to 1.6 grams per kilogram of body weight daily during energy restriction, well above the standard dietary recommendation.
If nausea or low appetite make eating whole-food sources difficult, protein supplementation is a practical bridge, not a permanent solution.
Resistance training forms the other half of that equation. "Muscle acts as your body's engine for burning calories and managing blood sugar," says Dr. Sangeeta Kashyap. "The more muscle you have, the more efficiently your body processes energy." Most clinical guidance recommends at least two full-body strength sessions per week, building gradually from baseline.
For people with kidney disease, older adults managing frailty, or patients on complex diabetes regimens, these targets are not one-size-fits-all. "Talk to your doctor about your specific health goals," says Dr. W. Scott Butsch, an obesity medicine specialist. "Together, you can come up with a plan that works best for you."
Muscle reduction during weight loss is not a GLP-1 phenomenon. It is a weight loss phenomenon. But the speed and scale of these medications have pushed it to the center of nutrition science, consumer behavior, and a rapidly expanding market that is still catching up to the evidence.
Taryn J. Mitchell, from North Carolina, lost 40 pounds in under a year. She lost some muscle along the way, too, but followed her doctor's guidance, picked up resistance bands and light weights, and kept moving.
As the weight came off, she found herself doing Pilates, moving with ease, and joining her daughters on the slopes rather than watching from the sidelines. "It's honestly given me a sense of freedom," she said.
Her story is one version of what informed GLP-1 use can look like. It also illustrates why the science matters more now than ever, and why research, clinical education, and honest public conversation need to grow as fast as the prescriptions do.
This story was produced by NutraBio and reviewed and distributed by Stacker.
Reader Comments(0)